|
Workshop
[In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
Speakers:
Yoshiko Stowell, Kenai Therapeutics; Vatzaki Efstratia, EMA; Jay Fajiculay, FDA; Kristina Luong, FDA; Huong Huynh, Critical Path Institute (C-Path); Bargavi Elangovan, Beigene; Xiling Song, Beigene; William Salminen, Premier Research; Yoshimasa Shimoto, CMIC Holdings; Brandon Rice, Weave
Organizers:
Snow Ge (BridgeBio), Yoshiko Stowell (Kenai Therapeutics)
Date:
2024-10-10
Time:
8:45-17:15 Pacific Time
Registration fee:
Regular attendees: $295; Academic/Students/Postdocs/Out-of-Pocket: $45; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $975; Lunch Sponsorship: $1250; On-site Registration: $500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(2)Elemental Machines; Meadowhawk Biolabs
Registration: http://www.PBSS.org
Registration deadline:2024-10-08
(it will close sooner if the seating cap is reached)
About the Topic
This workshop aims to equip attendees with the knowledge and strategies necessary to effectively navigate the complex and dynamic regulatory environment in drug development. This workshop will cover IND/NDA submission strategies (overall and CMC), EMA’s efforts to facilitate MAA submissions, overview of PMDA submission strategies and opportunities, impact of public-private partnerships in regulatory science, best practices and strategies in Regulatory Information Management (RIM) and Artificial Intelligence (AI) in regulatory lifecycle.
Time (PST) |
Topic |
Presenter(s) |
8:45 – 8:55 am |
PBSS Welcome and Introduction |
Snow Ge, PhD, BridgeBio and Co-chair, scientific program, PBSS |
8:55 – 9:05 am |
Overview of Regulatory Submissions 101, NDA, MAA, and J-NDA |
Yoshiko Stowell, PhD, RAC, PMP, Vice President Regulatory Affairs, Kenai Therapeutics |
9:05 – 9:40 am |
Good Practices for the MAA Submission and Interactions With the EMA |
Efstratia Vatzaki, PhD, Senior Regulatory Affairs Specialist, EMA |
9:40 – 10:15 am |
Part I: FDA Strategies for Efficient Drug Development Programs |
Jay Fajiculay, PharmD, Senior Regulatory Health Project Manager, Gastroenterology, FDA |
10:15 – 10:50 am |
Part II: Best Practices for Utilizing FDA Interactions in Drug Development Programs |
Kristina Luong, PharmD, BCPS, Regulatory Health Project Manager, Gastroenterology, FDA |
10:50 – 11:10 am |
Regulators’ panel discussion |
Yoshiko Stowell, Efstratia Vatzaki, Jay Fajiculay, and Kristina Luong |
11:10 – 11:20 am |
Morning Major Sponsor Presentation |
BioIVT |
11:20 – 11:40 am |
Break and Vendor Show |
- |
11:40 – 11:50 am |
Clinical Trial Information System(CTIS): What you need to know? |
Yoshiko Stowell, PhD, RAC, PMP, Vice President Regulatory Affairs, Kenai Therapeutics |
11:50 am – 12:25 pm |
Harnessing the Power of Patient Data: Impact of Public-Private Partnerships in Regulatory Science and Drug Development |
Huong Huynh, PhD, Director of Regulatory Science, Critical Path Institute (C-Path) |
12:25 – 1:25 pm |
Lunch |
- |
1:25 – 1:45 pm |
Best practices and Strategies in Regulatory Landscape: Data Quality and Data-centric Approach |
Bargavi Elangovan, Associate Director, Regulatory Information Management, Biogen |
1:45 – 2:20 pm |
Strategies and Best Practices to Accelerate Right First-Time CMC Dossier Readiness for Global Regulatory Submissions |
Xiling Song, MS, VP, Global Head of Regulatory CMC, Beigene |
2:20 – 2:50 pm |
Break and Vendor Show |
- |
2:50 – 3:25 pm |
Streamlining Repurposed Drug Development: 505(b)(2) NDA Strategies |
Gregory A. Meyer, RAC, CQA, VP of Regulatory Affairs, Premier Research
William (Willie) Salminen, PhD, DABT, RAC, VP of Regulatory Toxicology and Clinical Pharmacology, Premier Research
|
3:25 – 4:00 pm |
Changes in Japan Regulatory Environment and Implication for Drug Development |
Yoshimasa Shimoto, PhD, Partner, Consulting and Navigation Unit, CMIC Holdings |
4:00 – 4:35 pm |
Regulatory Lifecycle + AI: Where, how, and when AI can streamline and accelerate |
Brandon Rice, MS, Chief Product Officer, Weave |
4:35 – 5:15 pm |
Panel discussion and/or interactive session |
Ann Lucchesi, Bargavi Elangovan, Huong Reagan, Xiling Song, William Salminen, and Yoshimasa Shimoto, Brandon Rice |
5:15 – 6:15 pm |
Happy Hour |
- |
About the SpeakersDr. Yoshiko Stowell is VP of Regulatory Affairs at Kenai Therapeutics. She has over 20 years of experience in drug development. Additional roles include Head of RA at Neuron23, VP of RA and QA at AmyriAD Therapeutics and Sr. Director of RA at Eidos Therapeutics, BridgeBio Pharma. She is the Chair of the Regulatory Affairs Professional Society (RAPS) San Francisco Bay Area Chapter. She received her PhD in Pharmaceutical Science from University of the Pacific, MS in Chemical Engineering from University of Oklahoma, and BS in Chemistry from Tokyo University of Science.
Efstratia Vatzaki is a Senior specialist in the Regulatory Affairs of European Medicines Agency in Amsterdam, The Netherlands. Having been at the Agency for almost 20 years, she worked in different positions in Evaluation of medicines, Pharmacovigilance and Transparency. Efstratia was involved in academic research in several institutes in Europe (Pasteur Institute in Paris, France; CNRS in Orleans, France; and Bath University, UK), after receiving her PhD in Biochemistry and Immunology from University of Athens in Greece. Efstratia is a chemist by training.
Jay Fajiculay, PharmD, is a Senior Regulatory Health Project Manager with FDA’s Office of New Drugs, supporting the Division of Gastroenterology. Dr. Fajiculay first joined FDA in 2016, serving as the Designated Federal Officer for the Gastrointestinal Drugs Advisory Committee and Advisory Committee for Pharmaceutical Sciences and Clinical Pharmacology, before transitioning to the Office of New Drugs in 2020. Dr. Fajiculay completed his Doctor of Pharmacy degree at Midwestern University’s Chicago College of Pharmacy in 2014, followed by a two-year Regulatory Pharmaceutical Fellowship in Drug Information co-sponsored by Purdue University, Eli Lilly and Company, and the FDA in 2016.
Dr. Kristina Luong, PharmD, BCPS, is a Senior Regulatory Health Project Manager with FDA’s Office of New Drugs. Dr. Luong first joined FDA as the Program Manager for the Division of Clinical Outcome Assessment, where she provided oversight of advice on clinical outcome assessments in drug development and policy. She prior to transitioned to her current role in 2022, supporting the Division of Gastroenterology. Dr. Luong earned a Bachelor of Science in Biochemistry from Virginia Tech in 2012 and a Doctor of Pharmacy from Virginia Commonwealth University School of Pharmacyin 2016. Following pharmacy school, she completed a PGY1 Pharmacy Practice Residency prior to joining FDA in 2018.
Bargavi Elangovan, BS, is Associate Director of Regulatory Information Management at Biogen. She has over 19 years of experience in Regulatory and R&D, focusing on streamlining business processes and implementation of IT solutions for leading pharmaceutical companies. At Biogen, she is responsible for the oversight of global regulatory systems, and previously, at Cognizant, she spearheaded the execution of multiple large-scale strategic engagements including RIM system implementation. Bargavi holds a Bachelor's degree in Electronics from Madras University and has obtained multiple professional certifications, including in Global Regulatory Strategy and Pharmaceuticals: EU and US Regulations from the Regulatory Affairs Professionals Society (RAPS).
Huong directs the Regulatory Science Program at Critical Path Institute, leading strategic discussions with FDA and EMA and working in cross-functional and multi-disciplinary collaborations to develop regulatory strategies for the endorsements of novel drug development tools such as biomarkers, clinical endpoints, patient-reported outcome measures, clinical trial simulation tools and other quantitative solutions to address unmet medical needs through scientific collaborations in the pre-competitive space. Huong has 20+ years of regulatory experience including as an FDA regulatory reviewer and contributed to leading new initiatives across diverse disease areas, including rare diseases, neurodegenerative disorders, metabolic diseases, and pediatric conditions.
Xiling has over 24 years of experience in the pharmaceutical industry and currently serves as Vice President, Global Head of Regulatory CMC at BeiGene, where she oversees global CMC-related submissions for more than 50 small molecule and biologics products. Before joining BeiGene in 2019, Xiling spent 15 years at Roche Genentech and 5 years at Boehringer Ingelheim, holding roles such as Analytical Scientist, Regulatory CMC Lead, Quality Product Lead, and CMC Project Lead. She actively engages in regulatory intelligence, collaborating with agencies like the FDA and China CDE, and holds a Master of Science degree in Analytical Chemistry.
William (Willie) Salminen, PhD, DABT, RAC has 25 years of drug development experience. He leads the Nonclinical and Clinical Pharmacology groups within Premier, which provides nonclinical and clinical pharmacology strategies, study requirements and designs, pharmacokinetic modeling, input on regulatory submissions, and addressing nonclinical and clinical issues (e.g., Clinical Holds). William’s key experience includes but is not limited to regulatory strategy and advice, nonclinical safety and toxicology strategy and advice, US FDA pre-IND meetings, IND applications and maintenance and NDA and BLA submissions. He has significant experience with 505(b)(2) NDAs and the unique regulatory, nonclinical, and clinical strategies involved with developing drugs under the 505(b)(2) pathway.
Yoshimasa Shimoto has provided strategic consulting and navigation to companies seeking to enter the Japanese pharmaceutical market. Prior to joining CMIC, he served as the Executive Vice President at Daiichi Sankyo RD Novare, overseeing the execution of clinical studies. At Daiichi Sankyo, he also had served as Vice President of Global Project Management and Asia Development, responsible for portfolio/project management of R&D and clinical study implementation in the Asian region, respectively. Dr. Shimoto received a PhD from the University of Tokyo and completed a research fellowship at the University of Michigan.
Brandon Rice is a Chief Product Officer at Weave. He and his team are building AutoIND, an AI-powered software platform to streamline every aspect of IND preparation. He is deeply committed to building products that positively impact human lives, create meaningful value for customers, and are delightful to use. Brandon has spent the majority of his career in life science startups, spanning drug manufacturing (new CGT manufacturing platforms), discovery (CRISPR-based target discovery), and diagnostics (multi-omic early cancer detection). Prior to his years in venture-backed companies, he co-founded a genomics services company that's still building genomes today. He is obsessed with the discovery of pragmatic applications for emerging technologies.
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapies
|
2024-12-05, [Free Online] Innovative Mass Spectrometry and Related Technologies for Life Science and Drug Development
|
2024-12-13, Why All These New Modalities?
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
|
2025-02-26, [In-Person] Demystifying Biopharma Business Development
|
2025-03-07, [In-Person] Clinical Trial Planning and Conduct: Fundamentals, Strategies and Best Practices
|
2025-03-27, [Free Online Workshop] Biotech Financing 101: from Angels, Government Agencies, Foundations and VCs
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Allucent
Bringing innovation to Biotech w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
|
Aroga Biosciences
Aroga Biosciences is an award-winning CRO specializing in scientific writing for nonclinical reports, INDs, CMC, and clinical documents.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
PharmaResources
Top-tier small molecule CRO/CDMO offering comprehensive supports from Medicinal Chemistry, DMPK, and CMC to GMP manufacturing for commercialization.
|
Aliri Bioanalysis
to the rescue! Pioneers in LCMS & Oligo bioanalysis w/ 30+ years of experience putting dev. programs back on track with quality data & fast timelines.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|